7 results about "Moraxella catarrhalis" patented technology

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The invention relates to the technical field of medical detection, and discloses a preparation method of a composition for detecting moraxella catarrhalis based on RPALFS, which comprises the steps of design and screening of a moraxella catarrhalis primer, design and verification of a probe, specificity verification, sensitivity verification and the like. The detection method is efficient, rapid, simple and portable, rapid and sensitive clinical detection on moraxella catarrhalis is achieved, the detection specificity is high, the detection time is short, and the detection method does not need to depend on special instruments and equipment.

The application provides a kit for detecting common pathogenic bacteria of otitis media based on a multi-enzyme constant temperature rapid nucleic acid amplification technology, which comprises a first primer pair for detecting Streptococcus pneumoniae, a second primer pair for detecting Haemophilus influenzae, a third primer pair for detecting Moraxella catarrhalis, a fluorescent probe combination and a colloidal gold probe combination; the nucleotide sequences of the first primer pair are SEQ ID NO: 2 and SEQ ID NO: 4 respectively, the nucleotide sequences of the second primer pair are SEQ ID NO: 9 and SEQ ID NO: 10 respectively, and the nucleotide sequences of the third primer pair are SEQ ID NO: 13 and SEQ ID NO: 18 respectively. The application provides a triple multi-enzyme constant temperature rapid synchronous detection kit and a detection method, which have high sensitivity, high specificity and convenient operation, and meet the requirements of rapid diagnosis on the spot in a clinic.

The invention discloses lactobacillus crispatus GG77 capable of repairing mucosal lesion and preventing pathogenic bacterium infection and application of the lactobacillus crispatus GG77, the lactobacillus crispatus GG77 is preserved in the China Center for Type Culture Collection, the preservation date is November 21, 2025, and the preservation number is CCTCC NO: M 20252646. Compared with the prior art, the invention provides a brand-new lactobacillus crispatus GG77 which mainly has the effects of repairing mucosal lesion and preventing pathogenic bacterium infection. The lactobacillus crispatus GG77 has high acid resistance, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or enterobacter cloacae. Experimental results show that the lactobacillus crispatus GG77 can repair mucosal lesion, prevent vaginitis recurrence, recover genital tract flora and promote calcium ion transport and absorption. Particularly, when the lactobacillus crispatus GG77 and the Witzia clostridium CN365 are combined for use, the lactobacillus crispatus GG77 and the Witzia clostridium CN365 have a synergistic effect, and the effect of transferring and absorbing calcium ions can be remarkably improved.

The present application relates to the field of ophthalmic drugs, and particularly relates to an ophthalmic composition, a preparation method and application thereof, the ophthalmic composition comprising a compound as shown in formula I, an osmotic pressure regulator, a pH regulator and water for injection; the pH value of the ophthalmic composition is 4.0-6.0; the concentration of the compound as shown in formula I is 0.1-3.0% w / v, and the concentration of the osmotic pressure regulator is 0.3-10.0% w / v; the antibacterial activity against Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis is 2-8 times that of levofloxacin and moxifloxacin hydrochloride; the antibacterial activity against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Pseudomonas aeruginosa is also strong, and is equivalent to that of levofloxacin and moxifloxacin hydrochloride; the irritation is small, the light stability and high-temperature stability are good, the quality and drug safety are guaranteed, and the application value is good.

The application discloses an antibacterial peptide, a preparation method thereof and application of the antibacterial peptide in preparation of a preparation for treating pneumonia, and belongs to the technical field of biological medicines. The antibacterial peptide is a mutant of endolysin derived from a gram-negative bacteriophage. The bacteriophage endolysin plays an antibacterial / killing effect by degrading bacterial cell walls, and basically does not produce drug resistance. Common pneumonia pathogenic bacteria, i.e., Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus, are used as indicator bacteria, three antibacterial peptide mutants EAMP-M1, EAMP-M2 and EAMP-M3 with better antibacterial effects are screened, experiments prove that the three antibacterial peptide mutants have better antibacterial effects on gram-positive bacteria and gram-negative bacteria, can be applied to prevention, treatment or auxiliary antibiotic treatment of common pneumonia infection, and can be used in the field of medical instruments, such as sterilization of surgical instruments, and have a wide and good market application prospect.

The present invention relates to an antibacterial composition against pathogenic bacteria, the composition comprising streptococcus salivarius g7 and lactobacillus plantarum gspe05, and specifically, exhibits high antibacterial activity against one or more bacteria selected from the group consisting of Bacillus cereus, Listeria monocytogenes, Salmonella typhimurium, Streptococcus mutans, Porphyromonas gingivalis, and Moraxella catarrhalis, and thus can contribute to the improvement of intestinal diseases, oral diseases, and respiratory diseases caused by these pathogenic strains.